Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
Mark Ayers, W. Fraser Symmans, James Joseph Stec et al. · Journal of Clinical Oncology · 2004
Purpose The goal of this study was to examine the feasibility of developing a multigene predictor of pathologic complete response (pCR) to sequential weekly paclitaxel and fluorouracil + doxorubicin + cyclophosphamide (T/FAC) neoadjuvant chemotherapy regimen for breast cancer. Patients and Methods All patients underwent one-time pretreatment fine-needle aspiration to obtain RNA from the cancer for transcriptional profiling using cDNA arrays containing 30,721 human sequence clones. Analysis was performed after profiling, and 42 patients' clinical results were available, 24 of which were used for predictive marker discovery; 18 patients' results were used as an independent validation set. Results Thirty-one percent of patients had pCR (six discovery and seven validation), defined as disappearance of all invasive cancer in the breast after completion of chemotherapy. We could identify no single marker that was sufficiently associated with pCR to be used as an individual predictor. A multigene model with 74 markers (P ≤ .09) was built using data from the discovery samples and tested on the validation samples. Overall, a 78% (14 of 18) predictive accuracy was observed, with a 100% (three of three) positive predictive value for pCR, a 73% (11 of 15) negative predictive value, a sensitivity of 43% (three of seven), and a specificity of 100% (11 of 11). The expected response rate to T/FAC neoadjuvant therapy in unselected patients is 28%. Conclusion Our results suggest that transcriptional profiling has the potential to identify a gene expression pattern in breast cancer that may lead to clinically useful predictors of pCR to T/FAC neoadjuvant therapy.
Cited by 567 works. doi:10.1200/jco.2004.05.166
Authors
- Mark Ayers
- W. Fraser Symmans
- James Joseph Stec
- Andrew I. Damokosh
- Edwin A. Clark
- Kenneth R. Hess
- Michael Lecocke
- Daniel J. Booser
- Nuhad K. Ibrahim
- Vicente Valero
- Melanie Royce
- Banu Arun
- Gary J. Whitman
- Jeffrey S. Ross
- Nour Sneige
- Gabriel N. Hortobágyi
- Lajos Pusztai
References
- Statistical Learning Theory
- Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
- Gene expression profiling predicts clinical outcome of breast cancer
- Prediction of central nervous system embryonal tumour outcome based on gene expression
- Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
- Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel